Navigating the Adoption of Earlier CAR T-Cell Therapy in Multiple Myeloma

Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.

Doris Hansen, MD, discusses the earlier use of CAR T-cell therapy in myeloma and ongoing barriers to access.

Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.

Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, discusses why CAR T-cell therapy could be considered at first relapse in multiple myeloma.

Hamza Hashmi, MD, outlines considerations for identifying patients with early relapsed/refractory multiple myeloma as candidates for CAR T-cell therapy.